LY3884963 clinical trials

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

This study is testing a new medicine, LY3884963, for Frontotemporal Dementia (FTD) caused by a specific gene change. It will check if the medicine is safe, how it affects a protein called progranulin, and if it helps patients.